PD-1 blockade is a successful immunotherapy in a subset of patients with cancer. However clinical challenges of this therapy, such as optimal duration, immune-related adverse events or atypical tumor evolution, are poorly understood at the immune level.

My research focuses on a better understanding of how immune cells, in particular T cells, act in some of these clinical challenges.